Adma Biologics (ADMA) Notes Payables (2011 - 2017)

Adma Biologics (ADMA) posted Notes Payables of $6.7 million for Q2 2017, little changed on a QoQ basis from $6.7 million in Q1 2017.

Adma Biologics (ADMA) Notes Payables (2011 - 2017) Analysis & Trends

Adma Biologics' Notes Payables history runs 3 years deep, the most recent figure standing at $6.7 million for Q2 2017.

Quarterly Notes Payables changed N/A year-over-year to $6.7 million in Q2 2017, while the trailing twelve-month figure through Jun 2017 was $6.7 million (changed N/A YoY) and the FY2016 annual result came in at $6.1 million, changed N/A from the prior year.
Notes Payables was $6.7 million for Q2 2017 at Adma Biologics, roughly flat from $6.7 million in the prior quarter.
Across five years, Notes Payables topped out at $6.7 million in Q1 2017 and bottomed at $6.1 million in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Adma Biologics	1.99 Bn	1.91 Bn	88.82 Mn

Download Data